Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02207010 · ClinicalTrials.gov registry record · Early Phase 1
A Phase 0 Study of AZD1775 in Recurrent GBM Patients
A Early Phase 1 study, sponsored by St. Joseph's Hospital and Medical Center, Phoenix.
- Completed
- Registry status
- Early Phase 1
- Development phase
- 20
- Enrollment target
NCT02207010 is a Early Phase 1 study that has completed, run by St. Joseph's Hospital and Medical Center, Phoenix. The registered enrollment target is 20 participants.
The verdict
NCT02207010, a Early Phase 1 study, has completed, sponsored by St. Joseph's Hospital and Medical Center, Phoenix.
- COMPLETED
- Registry status
- Early Phase 1
- Development phase
- 20 participants
- Enrollment target
Study Summary
This study would test how much of the new drug, AZD1775, is present in tumor, blood, and skin after one dose of the drug. The purpose of the study is not to treat the tumor, but to see if the drug actually gets into the tumor cells. This study does not replace routine cancer treatment.
Interventions
- BIOLOGICAL AZD1775
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 20 participants |
| Start Date | 2014-07 |
| Est. Completion | 2019-03-25 |
| Phase | Early Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02207010
The ClinicalTrials.gov registry entry for NCT02207010 describes a study currently listed as completed, categorized as Early Phase 1. The registered enrollment target is 20 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is St. Joseph's Hospital and Medical Center, Phoenix, which has 44 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which AZD1775 is the first listed.
NCT02207010 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02207010 about?
NCT02207010 is a clinical study titled "A Phase 0 Study of AZD1775 in Recurrent GBM Patients". This study would test how much of the new drug, AZD1775, is present in tumor, blood, and skin after one dose of the drug. The purpose of the study is not to treat the tumor, but to see if the drug actually gets into the tumor cells. This study does not replace routine cancer treatment.
What is the current status of trial NCT02207010?
This trial is currently completed. It is a Early Phase 1 study. The enrollment target is 20 participants. The study started on 2014-07. Estimated completion is 2019-03-25.
What interventions are being tested in trial NCT02207010?
The interventions under investigation include: AZD1775 (BIOLOGICAL).
Who is sponsoring clinical trial NCT02207010?
This trial is sponsored by St. Joseph's Hospital and Medical Center, Phoenix, which has 44 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.